Therapeutic Indications

Prostate cancer / adenocarcinoma

View all technologies

uPAR-Targeting Human Antibody for Treating Cancer and Fibrotic Diseases

06240

uPAR-targeting human VH antibodies offer potent, versatile cancer and fibrotic-disease therapy with VH-Fc formats.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Hepatology
Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Cirrhosis
Melanoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Xiaojie Chu
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-12-06
Collections: Cardiometabolic
Women's & Reproductive Health

Identification of Fully Human Antibodies

05676

Fully human PSCA-targeting antibodies enable potent ADCC and ADCs against PSCA+ cancers, including prostate tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Renal cell carcinoma (RCC)
Pancreatic adenocarcinoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-04-21

Compounds Targeting Androgen Receptor to Treat Castration-Resistant Prostate Cancer

02501

Novel compounds degrade androgen receptor in the nucleus, inhibiting AR signaling and CRPC tumor growth without cytotoxicity.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Lead Inventor: Zhou Wang
Department: Med-Urology
All Tech Innovators: Paul A. Johnston
John S. Lazo
Joel B. Nelson
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2011-06-10

Novel Senotherapeutic Agents for Cancer Therapy

06267

Senotherapeutic sGC activator cinaciguat induces apoptosis in senescent prostate cancer cells, reducing recurrence and BPH progression.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Urology
Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Aging
Lead Inventor: Anthony Kanai
Department: Med-Medicine
All Tech Innovators: Youko Ikeda
Anthony J. Kanai
Irina Valerjevna Zabbarova
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-01-12

Fusion Gene-Based Machine Learning Tool Enhances Prediction of Prostate Cancer Clinical Outcomes

06089

Fusion-gene based machine learning boosts prostate cancer recurrence predictions using 14 gene signatures across multiple cohorts.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Urology
Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Genetics
Lead Inventor: Jianhua Luo
Department: Med-Pathology
All Tech Innovators: Shuchang Liu
Jianhua Luo
George Michalopoulos
Date Submitted: 2022-07-01

Fully Human Antibodies Targeting Membrane Proximal Region in Human CEACAM5

05469

Fully human CEACAM5-targeting antibody binds membrane-proximal region with nanomolar affinity, high specificity, and potential NEPC therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-08-06

A Novel Treatment for Metastatic Prostate Cancer

06044

Novel allosteric AR modulators found to disrupt AR-TIF2 signaling, offering potential treatment for metastatic castration-resistant prostate cancer.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Lead Inventor: Paul Johnston
Department: Pharm-Pharmaceutical Science
All Tech Innovators: Carlos Jaime Camacho
Andrew P. Hinck
Paul A. Johnston
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-06-01

Advanced Methods for Diagnosing Prostate Cancer and Predicting Relapse

02406

CNV-based genome analysis predicts prostate cancer progression and relapse, enabling personalized diagnostics and targeted treatment planning.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Precision medicine
Clinical Decision Support
Lead Inventor: Jianhua Luo
Department: Med-Pathology
All Tech Innovators: Jianhua Luo
George Michalopoulos
Joel B. Nelson
Technology Readiness Level: 5. Analytical validation
Date Submitted: 2011-02-15

Instrument-Free Assay for In-Clinic Detection of Bladder or Prostate Cancer

03825

Colorimetric, instrument-free urine test detects bladder/prostate cancer via MMP-2/9–triggered Fe(II) release and Fenton reaction.

Technology Type: Diagnostic/Assay
Technology Subtype: Other Diagnostic/Assay
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Lead Inventor: Abhinav Acharya
Department: Chem/Petroleum Engineering
All Tech Innovators: Abhinav Prakash Acharya
Steven R. Little
Tatum Varut Tarin
Date Submitted: 2016-02-09

PSMA with Multiple Single-Chain and Domain Binders Treats Prostate Cancer

05717

PSMA-targeting VH-domain antibodies enable potent ADCs, ADCC, or CAR-T for prostate cancer with improved penetration.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-06-09

EAF1 and EAF2 Mouse Monoclonal Antibodies

02877

Novel EAF1/EAF2 mouse antibodies enable specific WB, IHC, ELISA, and IP use for transcription factors and cancer research.

Technology Type: Life Science Research Tool
Technology Subtype: Protein
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Lead Inventor: Xinhui Wang
Department: Med-Immunology
All Tech Innovators: Junkui Ai
Soldano Ferrone
Xinhui Wang MD, PhD
Date Submitted: 2012-08-29
Collections: Healthcare AI

Fully Human FAbs to IGF-1 and IGF-2

04929

Fully human IGF-1/IGF-2–binding Fabs block IGF signaling to curb cancer cell growth, offering novel therapeutics.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Ductal carcinoma (Breast cancer)
Colorectal cancer (CRC)
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-03-24
Collections: Women's & Reproductive Health

Human Antibody Domains and Fragments to CD276

06094

engineered fully human single-domain antibodies and Fabs targeting CD276 (B7-H3) for potent, broadly applicable cancer immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Melanoma
Glioblastoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Dontcho V. Jelev
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-07-06

Novel Targeted Gene Therapy for Cancers

06452

Targeted HSV1-tk genome editing at cancer fusion breakpoints to induce tumor cell death, offering genotype-specific therapy potential.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - CRISPR
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Hepatocellular carcinoma (HCC)
Lead Inventor: Jianhua Luo
Department: Med-Pathology
All Tech Innovators: Muhamuda Kader
Shuchang Liu
Jianhua Luo
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-07-06
Collections: Cell & Gene Therapy

PNA-Linked Electrochemical Biosensor Platform for Quantitative Analyte Detection

01548

A modular PNA-linked biosensor enables fast, highly sensitive electrochemical PSA detection with ready-made point-of-care applications.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Lead Inventor: Joanne Yeh
Department: Med-Structural Biology
All Tech Innovators: Joanne I-Ti Yeh
Date Submitted: 2007-08-09

Innovative Leukocyte Genomic CNV Analysis for Predicting Prostate Cancer Outcomes

03651

Leukocyte CNV profiling predicts prostate cancer outcomes; improves recurrence risk accuracy when combined with Gleason, Nomogram, and fusion status.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Lead Inventor: Jianhua Luo
Department: Med-Pathology
All Tech Innovators: Shuchang Liu
Jianhua Luo
George Michalopoulos
Date Submitted: 2015-06-16

Diagnostic Test and Drug Development for Benign Prostatic Hyperplasia

02090

Discovery of BPH-V retrovirus linked to hypomethylation; enables targeted diagnostics, antivirals, vaccines, and personalized BPH therapy.

Technology Type: Diagnostic/Assay
Technology Subtype: In vitro Diagnostic
Therapeutic Areas: Oncology
Urology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Other
Lead Inventor: Denise O'Keefe
Department: Med-Urology
All Tech Innovators: Denise Susan O'Keefe
Date Submitted: 2009-10-13